New flu vaccine with booster adjuvant enters first human tests
NCT ID NCT07349017
First seen Jan 17, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This early-stage trial tests a new flu vaccine that includes an adjuvant called BK-01, designed to boost the immune response. About 160 adults aged 18 and older will receive either the new vaccine, a standard flu vaccine, or a placebo. Researchers will monitor for side effects and measure antibody levels over 30 days to see how well the vaccine works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
influenza vaccine with BK-01 adjuvant
What this could lead to
If successful, this could lead to a more effective seasonal flu vaccine that provides better protection.
What could go wrong
This is a very early Phase 1 trial with only 160 participants, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.